Alzheimer’s Drug Discovery Foundation: Drug Development

If you are interested in the following opportunity, please contact Carole King at carole.king@med.usc.edu.

• LOI due: February 23, 2026
• Amount: $5,000,000 (no indirects)
• Project Period: Multi-year

Funds IND-enabling studies and early-phase clinical trials of promising drugs or devices for Alzheimer’s and related dementias, focusing on diverse, novel mechanisms tied to the biology of aging and emerging therapeutic areas. Anti-amyloid and cholinesterase inhibitor approaches are excluded.  Up to $5,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and recruitment.